{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:32:03Z","timestamp":1787236323836,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Nature Science Foundation","award":["81630086"],"award-info":[{"award-number":["81630086"]}]},{"name":"National Nature Science Foundation","award":["91529305"],"award-info":[{"award-number":["91529305"]}]},{"name":"National Nature Science Foundation","award":["81302809"],"award-info":[{"award-number":["81302809"]}]},{"name":"National Nature Science Foundation","award":["81672763"],"award-info":[{"award-number":["81672763"]}]},{"name":"National Nature Science Foundation","award":["81502122"],"award-info":[{"award-number":["81502122"]}]},{"name":"Strategic Priority Research Program","award":["XDA12020319"],"award-info":[{"award-number":["XDA12020319"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["14391901800"],"award-info":[{"award-number":["14391901800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Food Safety Research Center and Key Laboratory of Food Safety"}],"content-domain":{"domain":["ebiomedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ebiom.2016.11.026","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T15:18:45Z","timestamp":1479914325000},"page":"44-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Xiaoguang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2016.11.026_bb0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","article-title":"PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives","volume":"109","author":"Asati","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0015","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1016\/j.bmc.2013.04.059","article-title":"Novel artemisinin derivatives with potential usefulness against liver\/colon cancer and viral hepatitis","volume":"21","author":"Blazquez","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1369\/jhc.2008.952044","article-title":"Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma","volume":"57","author":"Bressenot","year":"2009","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0025","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1016\/j.bmcl.2015.05.067","article-title":"Synthesis of a novel series of fluoroarene derivatives of artemisinin as potent antifungal and anticancer agent","volume":"25","author":"Buragohain","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0030","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/jcb.24134","article-title":"Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest","volume":"113","author":"Casanova","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0035","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.bmc.2008.12.017","article-title":"Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against P. falciparum malaria parasites and HL-60 cancer cells","volume":"17","author":"Chadwick","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0040","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1582-4934.2008.00360.x","article-title":"Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy","volume":"13","author":"Chen","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0045","article-title":"Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0050","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.humpath.2013.05.001","article-title":"Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma","volume":"44","author":"Chen","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0055","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/onc.2012.261","article-title":"Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells","volume":"32","author":"Cotrim","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0060","article-title":"Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug","volume":"247597","author":"Crespo-Ortiz","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0065","first-page":"1051","article-title":"A cell cycle hypothesis of cooperative oncogenesis (review)","volume":"30","author":"Delaval","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0070","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1242\/jcs.129387","article-title":"Scribble regulates an EMT polarity pathway through modulation of MAPK-ERK signaling to mediate junction formation","volume":"126","author":"Elsum","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0075","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s10637-014-0149-7","article-title":"Dual inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors","volume":"32","author":"Ewald","year":"2014","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0080","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399409001239","article-title":"Anticancer activities of artemisinin and its bioactive derivatives","volume":"11","author":"Firestone","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/cbdd.12335","article-title":"Synthesis and evaluation of antimalarial properties of novel 4-aminoquinoline hybrid compounds","volume":"84","author":"Fisher","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0090","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1586\/era.12.69","article-title":"Tumor microenvironment regulates epithelial-mesenchymal transitions in metastasis","volume":"12","author":"Gao","year":"2012","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0095","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1158\/0008-5472.CAN-12-1223","article-title":"Microenvironmental regulation of epithelial-mesenchymal transitions in cancer","volume":"72","author":"Gao","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0100","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/1078-0432.CCR-08-0197","article-title":"Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action","volume":"14","author":"Hou","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.yexcr.2014.04.006","article-title":"Dual contribution of MAPK and PI3K in epidermal growth factor-induced destabilization of thyroid follicular integrity and invasion of cells into extracellular matrix","volume":"326","author":"Ingeson-Carlsson","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0110","doi-asserted-by":"crossref","first-page":"7956","DOI":"10.1038\/ncomms8956","article-title":"An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer","volume":"6","author":"Janzen","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0115","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10637-012-9873-z","article-title":"Development of artemisinin compounds for cancer treatment","volume":"31","author":"Lai","year":"2013","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0125","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1038\/sj.onc.1209091","article-title":"Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3\u2032 kinase\/AKT pathways","volume":"24","author":"Larue","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0130","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2174\/1568009611313040009","article-title":"Valeriana jatamansi constituent IVHD-valtrate as a novel therapeutic agent to human ovarian cancer: in vitro and in vivo activities and mechanisms","volume":"13","author":"Li","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0135","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-12-3258","article-title":"Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-kappaB","volume":"19","author":"Li","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0140","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","author":"Li","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0145","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2011.08.024","article-title":"Artemisinin: discovery from the Chinese herbal garden","volume":"146","author":"Miller","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0150","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","article-title":"Pten loss and RAS\/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem\/progenitor cells","volume":"72","author":"Mulholland","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrc1611","article-title":"Ovarian cancer metastasis: integrating insights from disparate model organisms","volume":"5","author":"Naora","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0160","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/13543776.2012.724063","article-title":"Artemisinin derivatives: a patent review (2006\u2013present)","volume":"22","author":"Njuguna","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0165","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ejmech.2014.05.028","article-title":"Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents","volume":"81","author":"Romagnoli","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3835(02)00005-8","article-title":"Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells","volume":"179","author":"Sadava","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0175","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ctrv.2013.03.009","article-title":"Targeting the PI3K\/AKT\/mTOR and Raf\/MEK\/ERK pathways in the treatment of breast cancer","volume":"39","author":"Saini","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ddmod.2006.05.006","article-title":"Models of ovarian cancer metastasis: murine models","volume":"3","author":"Sale","year":"2006","journal-title":"Drug Discov. Today Dis. Model."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0185","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399411002109","article-title":"PI3K\/AKT. MAPK and AMPK signalling: protein kinases in glucose homeostasis","volume":"14","author":"Schultze","year":"2012","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0190","article-title":"Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives","volume":"435713","author":"Shi","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0195","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.bmc.2010.01.001","article-title":"Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: a hybrid pharmacophore approach","volume":"18","author":"Solomon","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0200","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejphar.2015.04.048","article-title":"Chloroquine-based hybrid molecules as promising novel chemotherapeutic agents","volume":"762","author":"Srivastava","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0205","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijpharm.2011.05.003","article-title":"Absorption of the novel artemisinin derivatives artemisone and artemiside: potential application of Pheroid technology","volume":"414","author":"Steyn","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0210","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0215","doi-asserted-by":"crossref","first-page":"35231","DOI":"10.18632\/oncotarget.6159","article-title":"The combinatorial activation of the PI3K and Ras\/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence","volume":"6","author":"Thompson","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0225","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0230","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1248\/cpb.59.984","article-title":"Design, synthesis and antitumor activity of novel artemisinin derivatives using hybrid approach","volume":"59","author":"Xie","year":"2011","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0235","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1016\/j.bmcl.2009.05.076","article-title":"Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells","volume":"19","author":"Yang","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ebiom.2016.11.026_bb0240","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2583","article-title":"Beyond chemotherapy: targeted therapies in ovarian cancer","volume":"9","author":"Yap","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ebiom.2016.11.026_bb0245","first-page":"868","article-title":"Design, synthesis and antiproliferative activities of artemisinin derivatives substituted by N-heterocycles","volume":"50","author":"Zuo","year":"2015","journal-title":"Acta Pharm. Sin."}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396416305436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396416305436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T18:31:03Z","timestamp":1568572263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396416305436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":49,"alternative-id":["S2352396416305436"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2016.11.026","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2016.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}